Home > Resources > Whitepapers > Pharma & Biotech 2017 – Review of Outsourced Manufacturing

Pharma & Biotech 2017 – Review of Outsourced Manufacturing

January 26, 2017

This report is an update on the pharmaceutical outsourced manufacturing sector with the last Results’ report published in 2013. By 2015, the global Pharmaceutical market reached $1.11 trillion and is expected to continue growing at approx. 5.5% per annum. Our analysis estimates that the total outsourced manufacturing market reached $71.5bn in 2015 and is growing at 6.6%2. The sector’s faster growth above the pharmaceutical industry is helped by the anticipated transition to more outsourcing, as well as the good growth within particular subsectors.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Ottobock

All over the world, the name Ottobock is a synonym for high-quality and technologically outstanding medical technology products and services. The goal of helping to restore mobility to people with disabilities, and protect what mobility they have, stands behind each and every one of the company's products. Our conviction that quality of life is closely connected to a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company's nearly 100-year history and guides the development of new products in a focused manner.

OTHER WHITEPAPERS
news image

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More
news image

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More
news image

Potential measures to facilitate the productions of activepharmaceutical ingredients (APIs)

whitePaper | March 27, 2023

European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.

Read More
news image

How purpose-built tech can help pharmaceutical and life science companies streamline healthcare provider interactions

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.

Read More
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

PHARMACEUTICAL KEY ACCOUNT MANAGEMENT: HARNESSING SALES EXPERTISE TO DEVELOP UNIFIED STAKEHOLDER RELATIONSHIPS

whitePaper | November 25, 2022

To meet the needs of a growing range of external stakeholders, many life science companies are changing the ways that they disseminate information.

Read More

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Read More

Potential measures to facilitate the productions of activepharmaceutical ingredients (APIs)

whitePaper | March 27, 2023

European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.

Read More

How purpose-built tech can help pharmaceutical and life science companies streamline healthcare provider interactions

whitePaper | December 15, 2022

In today’s hypercompetitive pharmaceutical and life sciences (PLS) industry, strategic partnerships are more critical than ever. A smaller life sciences company may have relationships with hundreds of healthcare providers and healthcare organizations.

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably
produces high-quality drug products without extensive regulatory oversight.

Read More
More Whitepapers

Spotlight

Ottobock

All over the world, the name Ottobock is a synonym for high-quality and technologically outstanding medical technology products and services. The goal of helping to restore mobility to people with disabilities, and protect what mobility they have, stands behind each and every one of the company's products. Our conviction that quality of life is closely connected to a maximum of individual freedom and independence is a key concept that has been a major influence throughout the company's nearly 100-year history and guides the development of new products in a focused manner.

Events

National Medtech & Biotech Summit 2024

Conference